HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Transformation of Sézary syndrome into CD30+ anaplastic large T-cell lymphoma after alemtuzumab therapy with evidence of clonal unity.

Abstract
Alemtuzumab is a humanized mouse antibody targeting the CD52 cell surface, which has been effective in patients with advanced stage mycosis fungoides (MF) including erythrodermic MF and Sézary syndrome. There are a few descriptions of large cell transformation after its administration. A young patient with an acute onset of Sézary syndrome treated initially unsuccessfully with fludarabine and cyclophosphamide and later on successfully with alemtuzumab has been described. Three weeks after the beginning of therapy, however, she developed transformed T-cell lymphoma indistinguishable from CD30 anaplastic large-cell lymphoma. After bone marrow transplantation, the transformed CD30 cutaneous T-cell lymphoma recurred as a transformed CD30 plaque MF. All 3 types of lesions showed the same T-cell receptor clonal gene rearrangement, which supports the notion that Sézary syndrome, CD30 anaplastic large-cell lymphoma, and MF are interrelated.
AuthorsMariela Judith Nevet, Tsila Zuckerman, Dvora Sahar, Reuven Bergman
JournalThe American Journal of dermatopathology (Am J Dermatopathol) Vol. 37 Issue 1 Pg. 73-7 (Jan 2015) ISSN: 1533-0311 [Electronic] United States
PMID25548993 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Ki-1 Antigen
  • Alemtuzumab
Topics
  • Adult
  • Alemtuzumab
  • Antibodies, Monoclonal, Humanized (therapeutic use)
  • Antineoplastic Agents (therapeutic use)
  • Biomarkers, Tumor (analysis)
  • Biopsy
  • Bone Marrow Transplantation
  • Female
  • Gene Rearrangement, T-Lymphocyte
  • Genes, T-Cell Receptor
  • Humans
  • Immunohistochemistry
  • Ki-1 Antigen (analysis)
  • Lymphoma, Large-Cell, Anaplastic (genetics, immunology, pathology, surgery)
  • Mycosis Fungoides (genetics, immunology, pathology, therapy)
  • Sezary Syndrome (drug therapy, genetics, immunology, pathology)
  • Skin Neoplasms (drug therapy, genetics, immunology, pathology)
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: